Microbiota and Gastrointestinal Manifestations of Parkinson’s Disease with Arabic Translation of Gastrointestinal Dysfunction Scale
Objective: To investigate the frequency of occurrence of gastrointestinal tract GIT symptoms and their relation to patients’ clinical characteristics in addition the characteristics of gut…Olfactory neurons’ Substance P is highly expressed in Parkinson’s disease reflecting gastrointestinal dysfunction
Objective: To elucidate the role of Substance P in PD through molecular characterization of patients’ olfactory neurons. Background: Substance P is a neuropeptide largely expressed…Dietary protein redistribution influences the efficacy of levodopa/carbidopa intestinal gel (LCIG) infusion
Objective: To compare levodopa/carbidopa intestinal gel (LCIG) with equally distributed dietary protein (Diet_EDP) versus restricted to twice daily (Diet_RP) and Mediterranean diet (Diet_M). Background: Levodopa…Risk of Parkinson’s Disease due to Helicobacter Pylori and High Salt Consumption
Objective: The association between excessive salt consumption, susceptibility to H. pylori infection and risk of Parkinson's disease will be analyzed through scientific studies. Background: The…Non-motor Symptoms Progression in Parkinson´s Disease. A 4-year Follow-up Study.
Objective: The aim of the present study was to know how Non-motor Symptoms (NMS) change over time in patients with Parkinson´s disease (PD) comparing to…The N6-Methyladenosine mRNA Methylase METTL14 Regulates TLR4-mediated intestinal dysfunction in Parkinson’s Disease
Objective: The aim of this study is to explore the function and mechanism of RNA m6A modification in gut-derived inflammation of Parkinson's disease (PD). Background:…Safety in Levodopa/carbidopa Intestinal Gel (LCGI) titration in the Intensive Care Unit (ICU) setting for Parkinson’s Disease (PD) patient with severe dysphagia
Objective: Describe a PD patient with obsessive-compulsive disorder (OCD) and paranoid symptoms in whom treatment with LCIG was started in the ICU due to severe…Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson’s Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment
Objective: Describe a patient in which after starting continuous infusion of LECIG a large reduction of the LEDD is achieved. Background: Gastroparesis (GP) is one…Gut microbiota dysbiosis in Parkinson’s disease patients: a potential biomarker of disease severity and progression?
Objective: To investigate gut microbiota alterations in Parkinson's disease (PD) along disease progression. Background: Gut microbiota dysbiosis is considered a hallmark in PD1. However, it is…Efficacy of a four-strain probiotic on gut dysbiosis, motor and non-motor symptoms in Parkinson`s disease: a multicentre randomised controlled trial
Objective: To evaluate the effect of a four-strain probiotic (Lacticaseibacillus rhamnosus, Enterococcus faecium, Lactobacillus acidophilus, Lactiplantibacillus plantarum) on gut microbiota composition, motor and non-motor symptoms…
- 1
- 2
- 3
- …
- 9
- Next Page »